Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen.
Clear cell renal carcinomas are the most common form of kidney cancer and frequently are linked to biallelic inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. The VHL gene product, pVHL, has multiple functions including directing the polyubiquitylation of the HIF transcription factor. We screened 100 shRNA vectors, directed against 88 kinases, for their ability to inhibit the viability of VHL-/- renal carcinoma cells preferentially compared with isogenic cells in which pVHL function was restored. shRNAs for "hits" identified in the primary screen were interrogated in secondary screens that included shRNA titration studies. Multiple shRNAs against CDK6, MET, and MAP2K1 (also known as MEK1) preferentially inhibited the viability of 786-O and RCC4 VHL-/- cells compared with their wild-type pVHL-reconstituted counterparts. The sensitivity of pVHL-proficient cells to these shRNAs was not restored upon HIF activation, suggesting that loss of an hypoxia-inducible factor (HIF)-independent pVHL function formed the basis for selectivity. A small-molecule Cdk4/6 inhibitor displayed enhanced activity against VHL-/- renal carcinoma cells, suggesting that in some cases hits from shRNA screens such as described here might translate into therapeutic targets.
Bommi-Reddy
Archana
A
Department of Medical Oncology, The Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Almeciga
Ingrid
I
Sawyer
Jacqueline
J
Geisen
Christoph
C
Li
Wenliang
W
Harlow
Ed
E
Kaelin
William G
WG
Grueneberg
Dorre A
DA
D002292:Carcinoma, Renal Cell / Q000201:enzymology* / Q000473:pathology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D051361:Cyclin-Dependent Kinase 6 / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D048369:MAP Kinase Kinase 1 / Q000235:genetics; D010770:Phosphotransferases / Q000032:analysis* / Q000235:genetics / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011518:Proto-Oncogene Proteins / Q000235:genetics; D019859:Proto-Oncogene Proteins c-met; D034741:RNA, Small Interfering / Q000494:pharmacology; D017978:Receptors, Growth Factor / Q000235:genetics; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics*
D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D034741:RNA, Small Interfering; D017978:Receptors, Growth Factor; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D010770:Phosphotransferases; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; C495911:CDK6 protein, human; D051361:Cyclin-Dependent Kinase 6; D048369:MAP Kinase Kinase 1; C482125:MAP2K1 protein, human; C497446:VHL protein, human